Cell Reports
Volume 20, Issue 3, 18 July 2017, Pages 549-557
Journal home page for Cell Reports

Report
CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells

https://doi.org/10.1016/j.celrep.2017.06.054Get rights and content
Under a Creative Commons license
open access

Highlights

  • CRKL preferentially associates with p110β

  • CRKL knockdown inhibits p110β-dependent PI3K signaling in PTEN-null cancer cells

  • A PTEN/FAK/Src/p130Cas axis may activate CRKL/p110β in PTEN-null cancer cells

  • Inhibitors of Src and PI3K cooperate to inhibit growth of PTEN-null cancer cells

Summary

The p110β isoform of PI3K is preferentially activated in many tumors deficient in the phosphatase and tensin homolog (PTEN). However, the mechanism(s) linking PTEN loss to p110β activation remain(s) mysterious. Here, we identify CRKL as a member of the class of PI3Kβ-interacting proteins. Silencing CRKL expression in PTEN-null human cancer cells leads to a decrease in p110β-dependent PI3K signaling and cell proliferation. In contrast, CRKL depletion does not impair p110α-mediated signaling. Further study showed that CRKL binds to tyrosine-phosphorylated p130Cas in PTEN-null cancer cells. Since Src family kinases are known both to be regulated by PTEN and to phosphorylate and activate p130Cas, we tested and found that Src inhibition cooperated with p110β inhibition to suppress the growth of PTEN-null cells. These data suggest both a potential mechanism linking PTEN loss to p110β activation and the possible benefit of dual inhibition of Src and PI3K for PTEN-null tumors.

Keywords

PI3K
p110β
CRKL
Src
p130Cas
PTEN
protein interaction
cancer
proliferation
signaling

Cited by (0)

3

Lead Contact